Filter By Category
Archives
Share on -
CEVOSTAMAB
Generic Name: CEVOSTAMAB
ABSTRACT -
Cevostamab (BFCR4350A) is an investigational bispecific antibody targeting FcRH5 (Fc receptor homologue 5, a B-lineage antigen) on myeloma cells and CD3 on T cells, developed by Genentech/Roche for relapsed/refractory multiple myeloma. It redirects cytotoxic T lymphocytes to lyse FcRH5-expressing myeloma cells. Phase I data (CEVOSTAMAB study) demonstrated anti-myeloma activity and is being further evaluated in Phase I/II trials.
DOSAGE -
Intravenous infusion; step-up dosing schedule (e.g., 0.3 mg → 1 mg → 3.6 mg → target dose) to mitigate cytokine release syndrome; Q3W or Q2W maintenance dosing per protocol.
SIDE EEFECTS -
- Cytokine release syndrome (CRS)
- Fatigue
- Fever
- Cytopenias
- Infections
ALLERGIC REACTIONS -
These symptoms may indicate an allergic reaction and require immediate medical attention.
- Infusion hypersensitivity
- Anaphylaxis
- Urticaria
- Angioedema
DRUG INTERACTIONS-
- Corticosteroids used for CRS — may reduce T-cell activity
- Avoid live vaccines during treatment
- Additive myelosuppression with other myeloma therapies
PREAUTONS–
- Administer in hospital setting with CRS monitoring for all step-up doses
- ICANS (neurotoxicity) monitoring required
- Thromboprophylaxis per myeloma management guidelines
- Effective contraception required
WARNINGS –
- Severe CRS including Grade ≥3 reported — tocilizumab and corticosteroids must be available
- Tumour lysis syndrome risk in high disease burden patients
- Embryo-foetal toxicity — avoid in pregnancy
Share on -
. Developed by